Acceptance of external infusion pumps in patients with advanced breast cancer receiving continuous infusion fluorouracil

Tumori

Volumn 89, Issue 5, 2003, Pages 488-491

  Lombardi, Davide ^a   Di Lauro, Vincenzo ^a   Piani, Barbara ^a   Scuderi, Cristina ^a   Spazzapan, Simon ^a   Magri, Maria Donatella ^a   Crivellari, Diana ^a   Annunziata, Maria Antonietta ^a   De Cicco, Marcello ^a   Veronesi, Andrea ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Adaptation; Continuous infusion; Fluorouracil

Indexed keywords

FLUOROURACIL; NAVELBINE; PACLITAXEL;

ADAPTATION; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION PUMP; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; PERSONAL HYGIENE; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL BEHAVIOR;

EID: 10744222459     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900505     Document Type: Article

References (11)

1. Bow EJ, Kilpatrick MG, Clinch JJ: Totally implantable venous access port systems for patients receiving chemotherapy for solid tissue malignancies: a randomized controlled clinical trial examining the safety, efficacy, costs and impact on quality of life. J Clin Oncol, 17: 1267-1273, 1999.
2. Libutti SK, Horne MK: Vascular access and specialized techniques of drug delivery. In: Cancer. Principles and practice of oncology, De Vita VT, Jr, Hellman S, Rosemberg SA (Eds), pp 760-768, Lippincott, Williams and Wilkins, Philadelphia, 2001.
3. Crivellari D, Magri MD, Buonadonna A, Lombardi D, Paolello C, De Cicco M, Fantin D, Veronesi A: Continuous infusion fluorouracil in the management of advanced breast cancer: a phase II study. Tumori, 86: 42-45, 2000.
4. Lombardi D, Magri MD, Crivellari D, Spazzapan S, Paolello C, De Cicco M, Di Lauro V, Scuderi C, Veronesi A: Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy-refractory breast cancer. Ann Oncol, 11: 1041-1043, 2000.
5. Gridelli C, Di Maio M: Indication for venous ports in oncology comparing different experiences in Europe. Tumori, 87: S69-S70, 2001.
6. Zahnd D, Aebi S, Rusterholz S, Fey MF, Borner MM: Randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol, 10: 727-729, 1999.
7. Biffi R, Pozzi S, Pace U, Cenciarelli S, Zambelli M, Orsi F, Grasso RF, De Braud F, Andreoni B: Is there a real advantage in utilizing central venous ports in oncology surgery? An analysis of the cost-effectiveness ratio. Tumori, 87: 74-75, 2001.
8. Delmore JE, Horbelt DV, Jack BL, Roberts DK: Experience with the Groshong long-term central venous catheter. Gynecol Oncol, 34: 216-218, 1989.
9. Tolar B, Gould JR: The timing and sequence of multiple device-related complications in patients with long-term indwelling Groshong catheters. Cancer, 78: 1308-1313, 1996.
10. Mueller BU, Skelton J, Callender DPE, Marshall D, Gress J, Longo D, Norton J, Rubin M, Venzon D, Pizzo PA: A prospective randomized trial comparing the infectious and non-infectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol, 10: 1943-1948, 1992.
11. O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol, 12: 1247-1254, 2001.